Literature DB >> 12587953

Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis.

J Wojcicki1, K Kozlowski, M Drozdzik, M Wojcicki.   

Abstract

The aim of the study was to compare the feasibility of the MEGX (monoethylglycinexylidide) and antipyrine tests in reference to standard biochemical parameters used for liver assessment in cirrhotic patients. The study was carried out in 44 subjects: 14 healthy controls and 30 cirrhotic patients classified according to the Child-Pugh's score to subgroups A (n=11), B (n=12) and C (n=7). All subjects underwent two dynamic liver tests, i.e. MEGX (monoethylglycinexylidide) and antipyrine test in a crossover schedule with at least 5-day interval. For the MEGX, lidocaine was administrated intravenously, at a dose of 1 mg/kg, and blood samples for MEGX assay were collected after 15 minutes. MEGX concentrations were measured by fluorescence polarization immunoassay. The antipyrine concentrations were evaluated following a single oral administration of 1000 mg antipyrine. The blood was sampled for 24 hours after the drug administration, and antipyrine concentrations were measured spectrophotometrically. Standard biochemical parameters used for liver assessment were measured by means of routine laboratory methods. It was concluded that in patients liver with cirrhosis, liver dynamic tests were better predictors of hepatic function. The MEGX test was more feasible in clinical setting, but it was noted that antipyrine test was more sensitive in staging liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12587953     DOI: 10.1007/BF03192334

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

2.  Arterial ketone body ratio as a possible indicator for liver transplantation in fulminant hepatic failure.

Authors:  T Saibara; S Onishi; J Sone; N Yamamoto; Y Shimahara; K Mori; K Ozawa; Y Yamamoto
Journal:  Transplantation       Date:  1991-04       Impact factor: 4.939

Review 3.  Drug metabolism in liver disease.

Authors:  C W Howden; G G Birnie; M J Brodie
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

4.  The monoethylglycinexylidide test for grading of liver cirrhosis.

Authors:  L Fabris; R M Jemmolo; G Toffolo; D Paleari; S Viaggi; M Rigon; F Casagrande; F Lirussi; M Strazzabosco; C Cobelli; L Okolicsanyi
Journal:  Aliment Pharmacol Ther       Date:  1999-01       Impact factor: 8.171

5.  The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery.

Authors:  G Ercolani; G L Grazi; R Callivà; F Pierangeli; M Cescon; A Cavallari; A Mazziotti
Journal:  Surgery       Date:  2000-04       Impact factor: 3.982

6.  Caffeine clearance and biotransformation in patients with chronic liver disease.

Authors:  N R Scott; D Stambuk; J Chakraborty; V Marks; M Y Morgan
Journal:  Clin Sci (Lond)       Date:  1988-04       Impact factor: 6.124

Review 7.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Monoethylglicinexylidide test: a prognostic indicator of survival in cirrhosis.

Authors:  A Arrigoni; T Gindro; G Aimo; N Cappello; A Meloni; P Benedetti; G P Molino; G Verme; M Rizzetto
Journal:  Hepatology       Date:  1994-08       Impact factor: 17.425

9.  Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.

Authors:  G Engel; U Hofmann; H Heidemann; J Cosme; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1996-06       Impact factor: 6.875

10.  Antipyrine kinetics in patients with primary biliary cirrhosis.

Authors:  L L von Moltke; D R Abernethy; M M Kaplan; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  1993-01       Impact factor: 3.126

View more
  1 in total

1.  Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.

Authors:  G T Everson; M L Shiffman; J C Hoefs; T R Morgan; R K Sterling; D A Wagner; J L Desanto; T M Curto; E C Wright
Journal:  Aliment Pharmacol Ther       Date:  2008-12-01       Impact factor: 8.171

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.